"This is likely to discourage industry from investing in future influenza vaccines, and makes working with the US FDA uncertain and problematic," said Dorit Reiss, professor of law at UC Law San Francisco.
"They are refusing to review a new vaccine with a more flexible technology, while creating a real risk we will not have traditional vaccines for next year."…
https://www.theguardian.com/us-news/2026/feb/10/fda-moderna-flu-vaccine
No comments:
Post a Comment